vimarsana.com
Home
Live Updates
Extended Follow-Up Confirm Efficacy of First-Line Pembrolizu
Extended Follow-Up Confirm Efficacy of First-Line Pembrolizu
Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC
Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.
Related Keywords
,
Martinh Voss ,
International Metastatic Renal Cell Carcinoma Database Consortium ,
Merck Co Inc ,
Merck Sharp Dohme ,
Cancers Symposium ,
Genitourinary Medical Oncology Service ,
Memorial Sloan Kettering Cancer Center ,
Merck Sharp ,
Rhas Y ,
Non Clear Cell Rcc ,
Renal Cell Carcinoma ,
Pembrolizumab ,
Keytruda ,
Lenvatinib ,
Lenvima ,
Phase 2 Keynote B61 Trial ,
Nct04704219 ,
2024 Genitourinary Cancers Symposium ,
D ,
First Line Pembrolizumab Plus Lenvatinib ,